Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488095 | 0.93 | AOC3 (0.50) | AOC3CYP2C19TAAR1CNR2CHRM2 | |
| SCHEMBL13696394 | 0.86 | AOC3 (0.59) | AOC3TAAR1CHRM2HTR1AADRA2A | |
| SCHEMBL991930 | 0.82 | AOC3 (0.58) | AOC3TAAR1CNR2KCNH2SIGMAR1 | |
| SCHEMBL12082172 | 0.79 | TAAR1 (0.55) | AOC3CYP2C19TAAR1CNR2CHRM2 | |
| SCHEMBL6488567 | 0.76 | AOC3 (0.64) | AOC3CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL3726672 | 0.75 | NPSR1 (0.58) | CYP2C19TAAR1TDP1CYP1A2 | |
| SCHEMBL121248 | 0.75 | TSHR (0.39) | CYP2C19TAAR1ADRA2AADRA1ADRD3 | |
| SCHEMBL14647590 | 0.75 | CYP2C19 (0.57) | CYP2C19TAAR1CNR2CHRM2HTR1A | |
| Hydrochloric Acid SCHEMBL119950 | 0.74 | TSHR (0.38) | CYP2C19TAAR1ADRA2AADRA1ADRD3 | |
| SCHEMBL13569441 | 0.73 | CYP2C19 (0.55) | AOC3CYP2C19TAAR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238260-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOF | SAVCHUK, NIKOLAY FILIPPOVICH | 2024-07-18 | — | — | US | disclosed |
| US-20240238260-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOF | SAVCHUK, NIKOLAY FILIPPOVICH | 2024-07-18 | — | — | US | disclosed |
| EP-4137208-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, AND METHOD FOR PRODUCING SAME AND USING SAME | Savchuk, Nikolay Filippovich (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-106188043-A | Tetracyclic compound | 梅迪维新技术公司 | 2016-12-07 | — | — | CN | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2274307-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2217598-A1 | NEW TETRACYCLIC COMPOUNDS | Medivation Technologies, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-04-22 | — | — | US | disclosed |
| WO-2009120720-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES,INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099667-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | AOC3 341/4885CYP2C19 466/4885TAAR1 110/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | AOC3 819/4885CYP2C19 1698/4885TAAR1 39/4885 |
| US-20240238260-A1 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOF | HTR2A, HTR1A, HTR2B | AOC3 336/4885CYP2C19 462/4885TAAR1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.